Treatment with FTY720 has no beneficial effects on short-term outcome in an experimental model of intracerebral hemorrhage by unknown
Schlunk et al. Exp & Trans Stroke Med  (2016) 8:1 
DOI 10.1186/s13231-016-0016-z
RESEARCH
Treatment with FTY720 has no 
beneficial effects on short-term outcome 
in an experimental model of intracerebral 
hemorrhage
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Abstract 
Background: No evidence-based therapy is available for patients with acute intracerebral hemorrhage (ICH). In view 
of the profound inflammatory reaction in the perilesional tissue, we investigated in a well-characterized experimental 
model whether the administration of the immunomodulator fingolimod (FTY720) is neuroprotective in acute ICH.
Methods: ICH was induced by means of a stereotactic intrastriatal injection of collagenase type VII-S. FTY720 (1 mg/
kg) was administered intraperitoneally 1 h after ICH induction. Hematoma volume was assessed spectrophotometri-
cally at 24 h after ICH induction. The following endpoints were determined at 24 and 72 h, respectively: mortality rate 
and neurologic outcomes, edema formation, and MMP-9 activity.
Results: Twenty-four hour after ICH induction, hematoma volume was not statistically different between groups. 
No difference was found in mortality and neurologic outcomes at 24 and 72 h between FTY720 treated mice and 
controls. Edema formation was present in both groups on the ipsilateral side with no statistical difference between 
groups at both time points. No difference was found in MMP-9 levels after 24 and 72 h between groups.
Conclusions: Our results suggest that FTY720 has no beneficial effects in the acute phase of experimental ICH.
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Background
Intracerebral hemorrhage (ICH) accounts for approxi-
mately 15  % of all strokes worldwide. It is a severe dis-
ease with high mortality rates and poor functional 
outcomes [1]. A primary phase of “mechanical” brain 
damage induced by the expanding hematoma can be dis-
tinguished from a phase of secondary injury mediated 
by thrombin, free iron radicals, and inflammation [2]. 
In fact, leukocyte invasion into the brain starts immedi-
ately after the bleeding has occurred [3]. Inflammation 
contributes to the disintegration of the blood–brain-
barrier (BBB) and thus facilitates brain edema formation 
[2]. Besides neutrophils, CD3 positive lymphocytes have 
recently been identified in the perihematomal region in 
experimental ICH [4].
Fingolimod (FTY720) is an immune-modulating drug 
that has been approved for the treatment of patients with 
relapsing-remitting multiple sclerosis. Its anti-inflamma-
tory effect is mediated by agonist-induced internalization 
of S1P1-receptors on T-lymphocytes, which inhibits lym-
phocyte egress from primary and secondary lymphoid 
organs [4, 5]. Several experimental studies have shown a 
protective effect of FTY720 therapy in ischemic stroke in 
terms of reducing lesion size and cell death [5–9].
Considering the strong inflammatory response that fol-
lows hematoma formation, we speculated that FTY720 
treatment could be beneficial in the acute phase of ICH. 
Using a reliable animal model [10–13] and a well-pow-
ered study design, we investigated mortality, short-term 
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functional outcome, MMP-9 activation and edema for-
mation in mice treated with FTY720 or placebo.
Methods
Animals
All experiments were performed in accordance with the 
guide from the National Institute of Health for the care 
and use of laboratory animals. Throughout this study, 
male CD1-mice aged 12–16 weeks were used.
Study design
An overview of the experimental design is given in Fig. 1. 
Animals were randomly assigned to receive FTY720 or 
vehicle before any study procedures were undertaken. 
Endpoints were measured at two different time points 
(24  h and 72  h respectively). Group sizes were deter-
mined based on our previous studies using this model 
where we demonstrated the effect of anticoagulation and 
anticoagulation reversal on hematoma growth [10, 14–
16]. A first set of animals was used to determine hema-
toma volume and MMP-9 activity levels 24 h after ICH 
induction [n  =  20 mice, randomized to either FTY720 
treatment (n =  10) or placebo (n =  10)]. A second and 
third set was used to investigate edema formation at 
24 h [n = 22 mice, randomized to either FTY720 treat-
ment (n =  11) or placebo (n =  11)] or at 72  h [n =  19 
mice, randomized to either FTY720 treatment (n =  11) 
or placebo (n  =  8)], respectively. A fourth set of mice 
was used to determine MMP-9 levels at 72  h [n  =  11 
mice, randomized to either FTY treatment (n  =  5) or 
placebo (n  =  6)]. Functional outcome was investigated 
on all mice from the upper mentioned groups at 24 h in 
order to optimize group sizes for non-parametric testing 
[i.e., n = 42; FTY720 (n = 21), placebo (n = 21)] and at 
72  h [i.e., n =  30; FTY720 (n =  16), placebo (n =  14)], 
respectively.
Drug administration/white blood cell count
FTY720 (1 mg/kg body weight, dissolved in 0.9 % saline) 
or an equal amount of saline was administered via intra-
peritoneal injection in a blinded fashion 1  h after ICH 
induction. This FTY720 dosing regime has been proven 
to reduce the number of circulating lymphocytes and to 
provide neuroprotection in several experimental stud-
ies in ischemic stroke [5, 6]. To crudely demonstrate the 
effects of FTY720 or saline injection on the immune sys-
tem in our model, FTY720 or saline were injected into 
otherwise untreated mice. Twenty-four hours after injec-
tion, 700 µL of blood were drawn from the inferior caval 
vein under deep anesthesia with a 19-Gauge needle and 
transferred into EDTA microtainer tubes. A white blood 
cell count was performed on a fully automated analyzer 
at the Massachusetts General Hospital routine laboratory 
and results were confirmed by manual blood film review. 
Mean percentage of lymphocytes of saline or FTY720 
was 76.3 and 41.5 %, respectively (n = 2 per group). Mice 
that received FTY720 injection showed a marked shift 
towards a higher fraction of granulocytes (Fig. 2).
ICH induction
ICH was induced by means of a stereotactic injection 
of collagenase type VII-S (Sigma Aldrich, St. Louis, 
MO). For doing so, mice were anesthetized with iso-
flurane (1.5–2  %) in a 70  % N2O- and 30  % O2-mixture 
and placed in a stereotactic frame. A small borehole was 
drilled in the skull. A 32-Gauge needle (Hamilton 7000 
Fig. 1 Experimental design
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series, Hamilton, Reno, NV) was lowered into the right 
striatum at the following coordinates from the bregma: 
0.0 mm anterior, 2 mm lateral and 3.5 mm in depth. Over 
a period of 5 min, collagenase (0.1 U in 0.5 µL saline) was 
injected. The needle was left in situ for 10 min and was 
then slowly withdrawn over 5  min. After suturing, the 
animals were allowed to wake up and returned to their 
cages. Throughout the procedure, a heating lamp was 
used to maintain body temperature.
Functional outcome
Functional outcome was assessed at 24 and 72  h after 
ICH induction, respectively, by means of an established 
ordinal neuroscore and a standard hanging wire test 
[17]. For determining the neuroscore, mice were placed 
on a plate. Spontaneous movements were observed for 
1 min and categorized as follows: 0 = no apparent deficit; 
1 = slight deficit as instability during walking, but no cir-
cling; 2 = circling to the right with at least some straight 
movements and covering of distance; 3 = heavy circling 
to the right, no gain of distance or no movements at all. 
Dead animals were categorized as 4. For the hanging wire 
test, mice were placed on a wire approximately 30  cm 
above the surface, and the time to falloff was measured. A 
maximum of 60 s was allowed and the test was repeated 
three times.
Hematoma volume
Hematoma volume was quantified 24 h after collagenase 
injection. Briefly, the coagulated hematoma was care-
fully separated from the perilesional tissue on 1  mm 
brain slices using a scalpel and was transferred into a 
glass tube containing 3 ml of PBS. After homogenization, 
ultrasound was applied to lyse erythrocyte membranes. 
The samples were then centrifuged, and 250  µL of the 
supernatant was transferred into 1000  µL of Drabkins 
reagent. Absorption was determined in a spectropho-
tometer at 540 nm, and the results were expressed in µL 
of blood on the basis of a standard curve.
Brain edema measurements
To measure perilesional edema formation, mice were 
deeply anesthetized (isoflurane 5  %) and euthanized at 
24 and 72 h after collagenase injection, respectively. After 
removing the brain, a 3 mm block was cut with the nee-
dle insertion point in the middle using a mouse brain 
matrix and divided into left and right hemisphere. The 
striatum (and the hematoma on the ipsilateral side) was 
removed, and the cortex was weighed on aluminum foil 
(of known weight) with an electronic scale in order to 
obtain the wet weight. The samples were then dried for 
48 h at 80 °C and weighed again. Brain water content was 
expressed in mean percentage as followed: (wet weight - 
dry weight)/wet weight × 100. The cerebellum served as 
a control [18].
Brain MMP‑9 measurement
To determine MMP-9 activity, mice were deeply anes-
thetized at 24 or 72  h after ICH induction and tran-
scardially perfused with PBS. Brain specimens were 
obtained, and three 1 mm slices were cut using a 1 mm 
mouse brain matrix. Slices were divided into left and 
right hemisphere. The hematoma in the right striatum 
was carefully removed with a scalpel leaving no visible 
traces of blood. The cortex specimen were transferred 
into Eppendorf tubes and frozen at −80 °C. For MMP-9 
measurements, the contra- and ipsilateral cortex speci-
mens were homogenized in 600  µL cell lysis buffer 
including protease inhibitors on ice. Thereafter, the sam-
ples were centrifuged for 30 min with 13,000 rpm at 4 °C. 
Protein concentration of the supernatant was measured 
by means of the Bradford assay (Bio-Rad). According 
to the protein concentration, samples were prepared, 
loaded and separated by 10 % Tris–glycine gel with 0.1 % 
gelatin as substrate. After electrophoretic separation, 
the gel was renaturated and then incubated with devel-
oping buffer at 37 °C for 20 h. After developing, the gel 
was stained with 0.5 % Coomassie blue R-250 and then 
destained appropriately. MMP activity was quantified 
using an ImageJ tool via determination of the integrated 
density.
Statistical analysis
We used SPSS version 20 for statistical analyses. Paramet-
ric data were compared using the t test. Non-parametric 
data were compared by means of the Mann–Whitney-U 
Fig. 2 White blood cell count. FTY720 or saline were injected into 
otherwise untreated mice. Twenty-four hours after injection a white 
blood cell count was performed. Mean percentage of lymphocytes 
in saline or FTY720 treated mice was 76.3 % and 41.5 %, respectively 
(n = 2 per group)
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At 24  h, mortality rate was 5/21 FTY720 treated mice 
and 6/21 control mice (p  =  0.726). Neuroscores of 
FTY720 treated mice and control mice were found 
to be not different (p =  0.486; Fig.  3a). Regarding the 
results of the hanging wire test, there was also no indi-
cation of a possible protective effect of FTY720 treat-
ment as compared to the placebo treatment (p = 0.710; 
Fig. 3b).
Seventy-two hour after ICH induction, mortality rate 
was 3/16 FTY720 treated mice and 0/14 control mice 
(p  =  0.088). Functional outcome as measured on the 
neuroscore was again similar between FTY720 treated 
mice and controls (p =  0.191, Fig. 3c). Furthermore, no 
significant difference was found for the hanging wire test 
between groups (p = 0.816; Fig. 3d).
Hematoma volume
Hematoma volume was determined at 24  h after ICH 
induction. Mortality rate was 2/10 in the FTY720 treated 
group and 2/10 in the control group. Dead mice were 
included in the analysis. Mean hematoma volume was 
Fig. 3 Outcome 24 and 72 h after ICH induction. A 5-point score and a standard hanging wire test were used. No statistical difference was found 
between FTY720 treated mice and controls at 24 h using the 5-point-score [FTY720: n = 21, controls: n = 21; p = 0.486 (a)] or the standard hanging 
wire test [p = 0.710 (b)]. Similarly, evaluation 72 h after ICH induction did not reveal a significant difference between groups using the 5-point score 
[FTY720: n = 16, controls: n = 14; p = 0.191 (c)] or the hanging wire test [p = 0.816 (d)]
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7.1 ± 1.9 µL in control mice (n = 10) and 6.6 ± 2.2 µL 
in mice that received FTY720 injection (n =  10). There 
was no statistically significant difference between groups 
(p = 0.867; Fig. 4).
Brain edema formation
Edema measurements were performed at 24 h and at 72 h 
after collagenase injection, respectively. Mice that died 
within these observation periods were excluded from the 
analysis, as edema measurements cannot be reliably per-
formed in autolytic tissue.
After 24 h, mortality was 3/11 in the FTY treated group 
and 4/11 in the control group. Mean brain water content 
was 78.4 ±  0.3 % on the contralateral and 79.5 ±  0.3 % 
on the ipsilateral side in the control group (n  =  7; 
p = 0.018). In FTY720 treated mice, contralateral hemi-
spheres showed 78.9 ± 0.4 % and ipsilateral hemispheres 
80 ± 0.1 % of brain water content (n = 8; p = 0.033). No 
statistically significant difference was found between the 
ipsilateral sides among groups (p = 0.122; Fig. 5a).
Seventy-two hour after ICH induction, mortality 
rate was 3/11 in FTY720 treated mice and 0/8 in saline 
treated control mice. One mouse in the saline treated 
group died after outcome assessment but shortly before 
edema measurements and was therefore also excluded. 
Saline treated mice showed brain water contents of 
78.8 ± 0.3 % on the contralateral side, and of 80.3 ± 0.4 % 
on the ipsilateral side (n = 7; p = 0.013). In the FTY720 
treated group, brain water content was 78.6 ± 0.4 % on 
the contralateral side, and 80.3 ± 0.3 % on the ipsilateral 
side (n =  8; p =  0.005). Again, no significant difference 
was found between the ipsilateral sides among groups 
(p = 0.914; Fig. 5b).
Brain MMP‑9 measurements
MMP-9 activation was measured at 24 and at 72 h after 
ICH-induction, respectively. Mice that died within the 
observation period were excluded from this analysis. 
Specimens for MMP-9 measurements at 24  h were the 
same as were used for hematoma volume determination 
(see above).
Twenty-four hour after ICH induction, there was a 
trend towards a significant difference between groups 
(p  =  0.069; Fig.  6a), with lower MMP-9 activity sig-
nals in FTY720 treated animals as compared to con-
trols [assessed by means of the integrated density being 
405.2 × 10−3 ± 59.3 × 10−3 on the ipsilateral side of saline 
treated mice (n = 8) and 227.1 × 10−3 ± 68.5 × 10−3 on 
the ipsilateral side of FTY720 treated animals (n = 8)].
Seventy-two hour after ICH induction, mortality rate 
was 0/5 in FTY720 treated animals and 0/6 in controls. 
Differences in MMP-9 activity levels were not con-
firmed at 72 h after bleeding induction (saline ipsilateral: 
654.8 × 10−3 ± 38.4 × 10−3, n = 6; FTY720 ipsilateral: 
696 ×  10−3 ±  108.6 ×  10−3, n =  5; p =  0.708; Fig.  6b; 
Additional file 1: Figure S1). As compared to the ipsilat-
eral side, visual examination of gels with samples of the 
contralateral hemispheres showed clearly less MMP-9 
signal at both time points in all specimens.
Discussion
In our study, we analyzed whether FTY720 treatment 
provides short-term neuroprotection in acute ICH. 
Although our study was adequately powered and based 
on a well-defined and reliable experimental model of 
ICH, we were not able to demonstrate any differences 
in survival and functional outcome between FTY720 
treated mice and controls. Furthermore, there was no dif-
ference between groups in terms of brain edema forma-
tion, a critical component in the clinical course of ICH. 
Our results suggest that FTY720 treatment is not benefi-
cial after ICH in the early phase.
Acute ICH is followed by a profound inflammatory 
response. The hematoma is surrounded by an inflamma-
tory zone, characterized by BBB-breakdown and locally 
released chemokines which lead to the immigration of 
inflammatory cells from the blood stream into the peri-
hematomal zone [19–22]. In experimental studies on 
ischemic stroke, the subpopulation of T-lymphocytes has 
been identified to play a pivotal role in the progression 
of the disease, and anti-inflammatory regimes targeting 
these cells were suggested to provide neuroprotection 
[7, 9, 23, 24]. FTY720, has therefore been studied as a 
Fig. 4 Hematoma volume 24 h after ICH induction. Quantitative 
hemoglobin measurement in FTY720 treated animals (n = 10) and 
controls (n = 10) revealed no difference between groups (p = 0.867). 
Circles denote outliers that are more than 1.5 interquartile ranges 
away from the nearer edge of the box. Stars denote outliers that are 
more than 3 interquartile ranges away from the nearer edge of the 
box
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therapeutic option in ischemic stroke in several experi-
mental settings. With the exception of one, all of these 
studies reported FTY720 to be beneficial in terms of 
reducing infarct size and improving functional outcomes 
[5, 6, 8, 9, 25]. How these protective effects of FTY720 are 
mediated in detail is unknown. Peripheral immunomod-
ulation as the underlying mechanism is supported by a 
recently published study of Kraft et al., in which FTY720 
was tested in wild-type and lymphocyte-deficient 
RAG1−/− mice. Interestingly, in this study lymphocyte 
reduction in the cerebral vasculature of FTY720 treated 
ischemic mice attenuated microvascular thrombus for-
mation and increased cerebral blood flow [26]. This mod-
ulation of local thrombo-inflammatory processes in the 
ischemic brain microvasculature might not be operative 
in ICH and is a possible explanation for the absence of a 
positive treatment effect in our study.
Our results stand in contrast to the work of Rolland 
et  al., which reported FTY720 to be neuroprotective 
in experimental ICH in terms of improving functional 
outcomes and reducing brain edema formation [4]. The 
reasons for the divergent results are not entirely clear. 
Although significant, the reported data from Rolland 
et al. show rather small absolute and relative differences 
between groups concerning functional outcomes after 
24  h, which tend to diminish after 72  h. This questions 
the translational relevance of the findings. Furthermore, 
previous studies have shown that the number of lym-
phocytes in the brain is markedly increased 3 days after 
ICH onset [25]. One would therefore expect a stable or 
increasing effect of an anti-inflammatory therapy regime 
in this time frame rather than a decreasing. In the work 
by Rolland et  al., edema reduction in FTY720 treated 
animals was detected mainly in the basal ganglia of ipsi-
lateral hemispheres, based on wet-dry measurements. 
However, the hematoma itself was not removed. Edema 
Fig. 5 Edema formation 24 (a) and 72 h (b) after ICH Induction: 
Edema was assessed by means of the wet dry method in ipsi- and 
contralateral hemispheres. The cerebellum served as a control. 
Twenty-four hour after ICH induction, there was no statistical differ-
ence between ipsilateral hemispheres of FTY720 mice (n = 8) and 
controls (n = 7; p = 0.122). Similarly, at 72 h, no difference was found 
between groups (FTY720: n = 8, controls: n = 7; p = 0.914)
Fig. 6 MMP-9 levels in gelatin zymograms at 24 (a) and 72 h (b) after 
ICH induction: The graphs show mean values of integrated density. 
Twenty-four hour after ICH induction there was a lower ipsilateral 
signal in FTY720 treated animals (n = 8) as compared to controls 
(n = 8) with a trend towards significance (p = 0.069). At 72 h, no 
difference was found for the ipsilateral side between FTY720 treated 
mice (n = 5) and saline treated controls (n = 6; p = 0.708)
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values might therefore have been influenced by differ-
ences in ICH volume (which can vary in the collagenase 
model and which was not assessed). Also in a recently 
published paper, which reports FTY720 to reduce edema 
formation and to improve neurological function as early 
as 3  days after ICH, the hematoma was not removed 
before brain water content was measured [27]. Surpris-
ingly in this work absence of an effect of FTY720 on 
inflammation is stated. Instead the authors discuss that 
the prevention of BBB breakdown via S1P1 receptors 
may lead to decreased edema [28, 29]. In our study, we 
also investigated MMP-9 levels. MMP-9 is a proteolytic 
enzyme which is associated with BBB disruption and 
edema formation [28, 29]. FTY720 administration did 
not result in a protective effect regarding the BBB.
In an observational study of 23 patients with supraten-
torial ICH FTY720 reduced perihematomal edema and 
improved functional outcomes if administered within 
72  h of symptom onset [30]. One should be careful to 
generalize these results since the sample size was small 
and the study was not randomized. Furthermore con-
cerns were raised if edema measurements were accurate 
since time points of imaging varied between groups and 
different imaging modalities were used [31]. However, 
FTY720 was administered at later time points as in our 
study and for 3 consecutive days. Therefore we cannot 
exclude the possibility of a beneficial effect of FTY720 if 
given at later time points. ‬‬‬‬‬‬‬‬‬‬‬‬‬
Our study has several limitations. First, we used a sin-
gle experimental model and a single species of animals 
only. However, we believe that the large number of mice 
analyzed allows us to derive a reliable conclusion from 
our work for the tested hypothesis. Second, our study 
lacks a positive control. However, the researchers who 
conducted the experiments have longstanding experience 
with this experimental model and were able to demon-
strate the effects of anticoagulation and anticoagulation 
reversal on hemorrhage growth and functional outcome 
in several studies, bolstering the reliability of this model 
[10, 11, 14–16]. Lastly, we used only a single concentra-
tion of FTY720 with a single administration since we did 
not focus on analyzing long-term outcome in our mice. 
In studies showing a positive drug effect, FTY720 was 
administered once daily over 3  days [27, 32]. In one of 
these studies the 3-day regimen was compared to a sin-
gle administration and did only reveal mild differences 
between groups [32]. Furthermore a single administra-
tion with the identical dosage as in our study was used 
in experimental ischemic stroke showing a positive treat-
ment effect after 24 and 72 h [33, 34]. However, FTY720 
might have the potential to positively influence regen-
eration after ICH if administered over several days. This 
needs to be investigated in future translational studies.
In conclusion, our study suggests FTY720 not to be 
beneficial in acute ICH. However, further studies are 
needed to test its effectiveness in long-term outcome and 
regeneration.
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